[Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer].
The aim of our study was to determine phenazone pharmacokinetics as an index of hepatic microsomal enzymes activity and acetylation phenotype in women with breast cancer. Phenazone test was made in 41 women with breast cancer and in 25 healthy women as a control group. Acetylation phenotype was measured in 40 women with breast cancer and in 25 healthy women as a control group. The plasma concentration of phenazone was estimated by the spectrophotometric method of Brodie and associates. Acetylation phenotype was determined by the Bratton-Marshall method in Varley's modification. The mean phenazone half-life time (t0,5), shortened significantly and the mean elimination rate constant (K) increased in women compared with a group of healthy persons. Mean clearance rate was increased in women with breast cancer too, compared with a group of healthy women. Acceleration of phenazone elimination may suggest that in patients with breast cancer elimination of the other drugs metabolized by the pathway similar to phenazone also may be changed. This should be considered in selection of their dosage. We have observed the predominance of rapid acetylators in women with breast cancer comparing with healthy persons. This difference was not statistically significant. Our results of acetylation phenotype in women with breast cancer suggests that rapid acetylation may be a factor of susceptibility to breast cancer.
Orzechowska-Juzwenko
K
K
Katedry i Zakładu Farmakologii Klinicznej AM we Wrocławiu.
Wiela-Hojeńska
A
A
Milejski
P
P
Cieślińska
A
A
Hudziec
P
P
Adamska
M
M
D000107:Acetylation; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000097:blood*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood*; D000983:Antipyrine / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000378:metabolism*; D004198:Disease Susceptibility; D005260:Female; D006207:Half-Life; D006801:Humans; D008862:Microsomes, Liver / Q000201:enzymology*; D008875:Middle Aged; D010084:Oxidation-Reduction; D010641:Phenotype; D013418:Sulfamethazine / Q000097:blood*
D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D014408:Biomarkers, Tumor; D013418:Sulfamethazine; D000983:Antipyrine